Literature DB >> 9990413

Pharmacology of adapalene.

S Michel1, A Jomard, M Démarchez.   

Abstract

Adapalene, a synthetic retinoid, is a new drug proposed for the treatment of acne patients. Studies on the in vitro and in vivo pharmacology of adapalene have shown that it is very active on cell and tissue proliferation and differentiation. Furthermore, adapalene has anti-inflammatory potential as determined by its anti-AP1 activity. Adapalene interacts selectively with the nuclear receptors RAR beta and RAR gamma, and its activity on proliferation and differentiation can be blocked by a RAR beta-gamma antagonist. Because RAR beta is not expressed in human keratinocytes, the effect of adapalene on the major cell type of the epidermis is certainly mediated by its interaction with RAR gamma. The unique pharmacological properties of adapalene may explain why, when compared to tretinoin, it has an improved therapeutic ratio due to its better tolerance.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9990413     DOI: 10.1046/j.1365-2133.1998.1390s2003.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  18 in total

1.  A Meta-analysis to Investigate the Relation Between Fitzpatrick Skin Types and Tolerability of Adapalene-Benzoyl Peroxide Topical Gel in Subjects with Mild or Moderate Acne.

Authors:  Valerie D Callender; Norman Preston; Cris Osborn; Lori Johnson; Ronald W Gottschalk
Journal:  J Clin Aesthet Dermatol       Date:  2010-08

2.  In-vivo Effectiveness of Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel on Antibiotic-sensitive and Resistant Propionibacterium acnes.

Authors:  James J Leyden; Norman Preston; Cris Osborn; Ronald W Gottschalk
Journal:  J Clin Aesthet Dermatol       Date:  2011-05

3.  Adapalene 0.3% for the treatment of acne in women.

Authors:  Diane Berson; Andrew Alexis
Journal:  J Clin Aesthet Dermatol       Date:  2013-10

4.  Adapalene and Doxorubicin Synergistically Promote Apoptosis of TNBC Cells by Hyperactivation of the ERK1/2 Pathway Through ROS Induction.

Authors:  Umar Mehraj; Irfan Ahmad Mir; Mahboob Ul Hussain; Mustfa Alkhanani; Nissar Ahmad Wani; Manzoor Ahmad Mir
Journal:  Front Oncol       Date:  2022-07-06       Impact factor: 5.738

5.  Fixed-Dose Combination Gel of Adapalene and Benzoyl Peroxide plus Doxycycline 100 mg versus Oral Isotretinoin for the Treatment of Severe Acne: Efficacy and Cost Analysis.

Authors:  Pete Penna; Matthew H Meckfessel; Norman Preston
Journal:  Am Health Drug Benefits       Date:  2014-01

Review 6.  Transdermal penetration of topical drugs used in the treatment of acne.

Authors:  Andrea Krautheim; Harald Gollnick
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  Effects of adapalene-benzoyl peroxide combination gel in treatment or maintenance therapy of moderate or severe acne vulgaris: a meta-analysis.

Authors:  Rongying Zhou; Xian Jiang
Journal:  Ann Dermatol       Date:  2014-02-17       Impact factor: 1.444

8.  Comparative effects of retinoic acid or glycolic acid vehiculated in different topical formulations.

Authors:  Patrícia Maria Berardo Gonçalves Maia Campos; Lorena Rigo Gaspar; Gisele Mara Silva Gonçalves; Lúcia Helena Terenciane Rodrigues Pereira; Marisa Semprini; Ruberval Armando Lopes
Journal:  Biomed Res Int       Date:  2015-01-06       Impact factor: 3.411

9.  Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance).

Authors:  Julia D Labadie; Xinwei Hua; Tabitha A Harrison; Barbara L Banbury; Jeroen R Huyghe; Wei Sun; Qian Shi; Greg Yothers; Steven R Alberts; Frank A Sinicrope; Richard M Goldberg; Thomas J George; Kathryn L Penney; Amanda I Phipps; Stacey A Cohen; Ulrike Peters; Andrew T Chan; Polly A Newcomb
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-11-17       Impact factor: 4.090

10.  Moderate and Severe Inflammatory Acne Vulgaris Effectively Treated with Single-Agent Therapy by a New Fixed-Dose Combination Adapalene 0.3 %/Benzoyl Peroxide 2.5 % Gel: A Randomized, Double-Blind, Parallel-Group, Controlled Study.

Authors:  Linda Stein Gold; Jonathan Weiss; Maria Jose Rueda; Hong Liu; Emil Tanghetti
Journal:  Am J Clin Dermatol       Date:  2016-06       Impact factor: 7.403

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.